Details for New Drug Application (NDA): 020884
✉ Email this page to a colleague
The generic ingredient in AGGRENOX is aspirin; dipyridamole. There are twenty-two drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the aspirin; dipyridamole profile page.
Summary for 020884
Tradename: | AGGRENOX |
Applicant: | Boehringer Ingelheim |
Ingredient: | aspirin; dipyridamole |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE, EXTENDED RELEASE;ORAL | Strength | 25MG;200MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Nov 22, 1999 | TE: | RLD: | Yes |
Expired US Patents for NDA 020884
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Boehringer Ingelheim | AGGRENOX | aspirin; dipyridamole | CAPSULE, EXTENDED RELEASE;ORAL | 020884-001 | Nov 22, 1999 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription